97 related articles for article (PubMed ID: 209810)
1. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
Kogelnik HD; Meyer JH; Jentzsch K; Szepesi T; Kärcher KH; Maida E; Mamoli B; Wessely P; Zaunbauer F
Br J Cancer Suppl; 1978 Jun; 3():281-5. PubMed ID: 209810
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with misonidazole: high dose fractions versus daily low doses.
Kogelnik HD
Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
[TBL] [Abstract][Full Text] [Related]
3. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
Dische S; Saunders MI; Flockhart IR
Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
[TBL] [Abstract][Full Text] [Related]
4. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
Saunders ME; Dische S; Anderson P; Flockhart IR
Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808
[TBL] [Abstract][Full Text] [Related]
5. Initial clinical experience with the radiosensitizing nitroimidazole Ro 07-0582.
Jentzsch K; Kärcher KH; Kogelnik HD; Maida E; Mamoli B; Wessely P; Zaunbauer F; Nitsche V
Strahlentherapie; 1977 Dec; 153(12):825-31. PubMed ID: 601838
[TBL] [Abstract][Full Text] [Related]
6. Peripheral neuropathy related to misonidazole: incidence and pathology.
Urtasun RC; Chapman JD; Feldstein ML; Band RP; Rabin HR; Wilson AF; Marynowski B; Starreveld E; Shnitka T
Br J Cancer Suppl; 1978 Jun; 3():271-5. PubMed ID: 209809
[TBL] [Abstract][Full Text] [Related]
7. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
[TBL] [Abstract][Full Text] [Related]
8. The hypoxic cell sensitizer programme in the United States.
Phillips TL; Wasserman TH; JohnsonRJ ; Gomer CJ; Lawrence GA; Levine ML; Sadee W; Penta JS; Rubin DJ
Br J Cancer Suppl; 1978 Jun; 3():276-80. PubMed ID: 277245
[TBL] [Abstract][Full Text] [Related]
9. New side effect of the hypoxic cell sensitizer, misonidazole.
Partington J; Koziol D; Chapman D; Rabin H; Urtasun RC
Cancer Treat Rep; 1979 Jan; 63(1):123-5. PubMed ID: 217536
[TBL] [Abstract][Full Text] [Related]
10. [Clinical experience with daily doses of misonidazole (author's transl)].
Kogelnik HD; Reinartz G; Szepesi T; Seitz W; Wurst F; Mamoli B; Wessely P; Stark H
Strahlentherapie; 1980 Nov; 156(11):758-64. PubMed ID: 7434385
[TBL] [Abstract][Full Text] [Related]
11. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
Walker MD; Strike TA
Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094
[TBL] [Abstract][Full Text] [Related]
12. The effect of misonidazole as a hypoxic radiosensitizer at low dose.
Palcic B; Faddegon B; Skarsgard LD
Radiat Res; 1984 Nov; 100(2):340-7. PubMed ID: 6494445
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials of misonidazole in the United States.
Wasserman TH; Stetz J; Phillips TL
Cancer Clin Trials; 1981; 4(1):7-16. PubMed ID: 7214664
[TBL] [Abstract][Full Text] [Related]
14. Prolonged metronidazole administration with protracted radiotherapy: a pilot study on response of advanced tumours.
Karim AB
Br J Cancer Suppl; 1978 Jun; 3():299-301. PubMed ID: 277249
[TBL] [Abstract][Full Text] [Related]
15. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer.
Wasserman TH; Phillips TL; Johnson RJ; Gomer CJ; Lawrence GA; Sadee W; Marques RA; Levin VA; VanRaalte G
Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):775-86. PubMed ID: 227821
[No Abstract] [Full Text] [Related]
16. Misonidazole in the preoperative and radical radiotherapy of bladder cancer.
Awwad HK; El Merzabani MM; El Badawy S; Ezzat S; Akoush H; Abd El Moneim H; Saiid A; Soliman O; Khafagy M; Burgers MV
Cancer Clin Trials; 1980; 3(3):275-80. PubMed ID: 7438324
[TBL] [Abstract][Full Text] [Related]
17. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
Phillips TL; Wasserman TH; Johnson RJ; Levin VA; VanRaalte G
Cancer; 1981 Oct; 48(8):1697-704. PubMed ID: 6269723
[TBL] [Abstract][Full Text] [Related]
18. The effect of hypoxic radiosensitizer after mild hyperthermia in C3H mammary carcinoma.
Ohizumi Y; Murayama C; Maezawa H; Mori T
Tokai J Exp Clin Med; 1984 Oct; 9(4):331-7. PubMed ID: 6537042
[TBL] [Abstract][Full Text] [Related]
19. The demonstration of in vivo misonidazole tumour toxicity using post radiation hypoxia.
Gomer CJ; Johnson RJ; Hetzel FW; Lawrence G
Br J Cancer Suppl; 1978 Jun; 3():228-31. PubMed ID: 277234
[TBL] [Abstract][Full Text] [Related]
20. [Radiosensitization by hypoxic cell radiosensitizer--present status of radiosensitizer].
Murayama C; Mori T
Gan No Rinsho; 1990 Oct; 36(13):2249-54. PubMed ID: 2147449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
